Target
B cells
5 abstracts
Abstract
The efficacy of recombinant human adenovirus type 5 (H101) intra-tumor therapy in persistent/recurrent/metastatic gynecological cancer and the exploration of changes in tumor microenvironment.Org: The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China,
Abstract
Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.Org: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China, Shantou University Medical College, Shantou, China,
Abstract
Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis.Org: The University of Texas MD Anderson Cancer Center, University of Texas Health Science Center, MD Anderson Cancer Center at Cooper, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center,
Abstract
Translational analysis of combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer.Org: Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center,
Abstract
Immunocompetent and immunocompromised cancer populations: Post-vaccination humoral and cellular immune responses against SARS-CoV-2.Org: Hackensack Meridian Health Center for Discovery and Innovation, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Quest Diagnostics Inc.,